ClearNote Health remote jobs and company guide

At ClearNote Health, we are a dedicated team driven by a profound mission: to enable people at risk for high-mortality cancers to live longer, healthier lives. We were founded on the principle that early cancer detection is the key to improving patient outcomes, and this belief is at the core of everything we do. Formerly known as Bluestar Genomics, we have been on a five-year journey of rigorous scientific development and are proud to now be a commercial-stage company at the forefront of non-invasive cancer detection. Our work is centered around our proprietary Virtuoso™ epigenomics platform, a groundbreaking technology developed by scientists in the Stephen Quake laboratory at Stanford University. This platform leverages the latest advancements in artificial intelligence and bioinformatics to identify subtle, active biological changes that signal the presence of cancer, often long before symptoms appear. By analyzing cell-free DNA from a simple blood draw, we can detect some of the deadliest cancers, like pancreatic and ovarian, at their earliest, most treatable stages.

We are passionate about translating complex biology and cutting-edge technology into real-world, patient-centric products. Our team is a multidisciplinary group of adventurers and lifelong learners, united by a shared goal of making a tangible impact on people's lives. We foster a culture of bold innovation, encouraging our team to take initiative and apply their curiosity to solve some of the most pressing challenges in healthcare. Our lead programs, the Avantect® Pancreatic and Ovarian cancer tests, are designed for high-risk patient populations, providing a new level of clarity and hope where it's needed most. We are not just developing tests; we are building a future where a cancer diagnosis doesn't have to be a late-stage discovery. We are committed to redefining what's possible in cancer care, working together to win the fight against this devastating disease and give everyone a fighting chance.